Kyverna Therapeutics, Inc. (KYTX)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
KYTX price, last 12 months
Key stats
- Previous close
- $4.48
- Open
- $4.47
- Day range
- $4.30 – $4.62
- 52-week range
- $4.18 – $13.67
- Volume
- 824.9K
- Avg volume (20 days)
- 848.4K
- Market cap
- $319.3M
Performance
Technicals and fundamentals
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $319.3M